Still Time To Test Drive The Adaptive Pathways Pilot, EMA Tells Companies
This article was originally published in SRA
Executive Summary
Companies wanting to get their new, innovative drug into the EU's adaptive pathways pilot still have time do so, but their applications must be 'well developed' if they are to be considered for inclusion.